​

Aprea Therapeutics Stock (NASDAQ:APRE)

ForecastRevenueOwnershipFinancialsChart
Aprea Therapeutics by TradingView

Previous Close

$1.88

52W Range

$1.41 - $5.01

50D Avg

$1.77

200D Avg

$2.64

Market Cap

$9.74M

Avg Vol (3M)

$43.26K

Beta

1.58

Div Yield

-

APRE Company Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Oct 03, 2019

Website

APRE Performance

APRE Financial Summary

Dec 24Dec 23Dec 22
Revenue-$583.23K-
Operating Income$-14.32M$-15.47M$38.18M
Net Income$-12.96M$-14.29M$-224.88M
EBITDA$-14.32M$-14.28M$-112.48M
Basic EPS$-2.35$-3.95$-2.71K
Diluted EPS$-2.35$-3.95$-2.71K

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
JBIOJade Biosciences, Inc.
ADXNAddex Therapeutics Ltd
ASMBAssembly Biosciences, Inc.
CYCNCyclerion Therapeutics, Inc.
KRROKorro Bio, Inc.
FBRXForte Biosciences, Inc.
PTIXProtagenic Therapeutics, Inc.